Fig. 6.
Clioquinol and MK-2206 inhibit TNBC development, as assessed by intravital fluorescence microscopy. a Timeline of the experiments in the dorsal skinfold chamber model. b Body weight (g) of mice in control, clioquinol, MK-2206, and combination group on days 0, 3, 6, 10, and 14 after tumor transplantation (n = 10). c Stereomicroscopic images of 4T1 tumors (bordered by broken line) in mice from control, clioquinol, MK-2206, and combination group on day 14 after tumor transplantation. Scale bar: 2 mm.d Tumor size (mm2) in control, clioquinol, MK-2206, and combination group on days 0, 3, 6, 10, and 14 after tumor transplantation, as assessed by intravital fluorescence microscopy (n = 10). e Intravital fluorescence microscopic images of tumor microvessels in control, clioquinol, MK-2206, and combination group on day 14 after tumor transplantation. Scale bar: 120 μm. f Functional microvessel density (cm/cm2) of 4T1 tumors in control, clioquinol, MK-2206, and combination group on days 0, 3, 6, 10, and 14 after tumor transplantation, as assessed by intravital fluorescence microscopy (n = 10). g-i Diameter (µm; g), centerline RBC velocity (mm/s; h), and volumetric blood flow (pL/s; i) of tumor microvessels in control, clioquinol, MK-2206, and combination group, as assessed by intravital fluorescence microscopy (n = 10). Means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. (b, d, f, g-i: one-way ANOVA with Tukey’s multiple comparisons test)